Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Association between elevated cytokeratin 18 (CK-18) levels and hepatocyte death has made circulating CK-18 a candidate biomarker to differentiate non-alcoholic fatty liver from non-alcoholic steatohepatitis (NASH). Yet studies produced variable diagnostic performance. We aimed to provide summary estimates with increased precision for the accuracy of CK-18 (M30, M65) in detecting NASH and fibrosis among non-alcoholic fatty liver disease (NAFLD) adults. METHODS: We searched five databases to retrieve studies evaluating CK-18 against a liver biopsy in NAFLD adults. Reference screening, data extraction and quality assessment (QUADAS-2) were independently conducted by two authors. Meta-analyses were performed for five groups based on the CK-18 antigens and target conditions, using one of two methods: linear mixed-effects multiple thresholds model or bivariate logit-normal random-effects model. RESULTS: We included 41 studies, with data on 5,815 participants. A wide range of disease prevalence was observed. No study reported a pre-defined cut-off. Thirty of 41 studies provided sufficient data for inclusion in any of the meta-analyses. Summary AUC [95% CI] were: 0.75 [0.69-0.82] (M30) and 0.82 [0.69-0.91] (M65) for NASH; 0.73 [0.57-0.85] (M30) for fibrotic NASH; 0.68 (M30) for significant (F2-4) fibrosis; and 0.75 (M30) for advanced (F3-4) fibrosis. Thirteen studies used CK-18 as a component of a multimarker model. CONCLUSIONS: For M30 we found lower diagnostic accuracy to detect NASH compared to previous meta-analyses, indicating a limited ability to act as a stand-alone test, with better performance for M65. Additional external validation studies are needed to obtain credible estimates of the diagnostic accuracy of multimarker models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent meta-analysis proposed K-18 values between 127–191 U l−1 for ruling-out MASH at fixed sensitivity levels and 304–399 U l−1 to rule-in MASH at fixed specificity levels32.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199 · cited 1×
“The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [18] was used to assess methodological quality of all available full text studies.”
Self-citationDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The NAFLD Activity Score (NAS) [16] is the most commonly used pathologic criterion for evaluating NASH.”
MethodYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 4×
“He reports research grant funding from Abbvie, Allergan/ Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd., Vertex; consultancy on behalf of Newcastle University for Abbott Laboratories, Acuitas Medical, Allergan/ Tobira, Blade, BNN Cardio, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Co…”
BackgroundInfluentialEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Reitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369 · cited 1×
“Heterogeneity between and within studies was incorporated by calculating 95% prediction intervals [20].”
MethodSelf-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · cited 1×
“Fibrosis is the strongest predictor for long-term clinical outcomes in NAFLD patients, thereby, a key target event for patient stratification and clinical trial recruitment [4].”
BackgroundSampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293 · cited 1×
“Parameters such as mean age, BMI and disease prevalence were not sources of major heterogeneity between the present and previously published meta-analyses [61].”
ResultYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073 · cited 4×
“He reports research grant funding from Abbvie, Allergan/ Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd., Vertex; consultancy on behalf of Newcastle University for Abbott Laboratories, Acuitas Medical, Allergan/ Tobira, Blade, BNN Cardio, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Co…”
BackgroundInfluentialFeldstein, A. E., Wieckowska, A., Lopez, R. A., Liu, Y.-C., Zein, N. N., & McCullough, A. J. (2009) · Hepatology · doi:10.1002/hep.23050 · Cited by 712 · cited 3×
“Feldstein 2009 [8] USA 139 (88) NASH 50 Biopsy proven NAFLD 34.”
BackgroundWieckowska, A., Zein, N. N., Yerian, L. M., Lopez, R. A., McCullough, A. J., & Feldstein, A. E. (2006) · Hepatology · doi:10.1002/hep.21223 · Cited by 670 · cited 1×
“Wieckowska 2006 [48] USA 39 (21) NASH 31 Biopsy proven NAFLD 31.”
BackgroundWong, V. W., Chan, W., Chitturi, S., Chawla, Y., Dan, Y. Y., Duseja, A., Fan, J., Goh, K., Hamaguchi, M., Hashimoto, E., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13857 · Cited by 506 · cited 2×
“The Asia-Pacific Working Party on NAFLD [14] similarly concluded modest performance, referencing a meta-analysis of 10 studies [15].”
BackgroundMethodKwok, R., Tse, Y. ‐., Wong, G. L. ‐., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L. ‐., & Wong, V. W. ‐. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12569 · Cited by 405 · cited 3×
“In recommendations by the EASL-EASD-EASO Clinical Practice Guidelines [12] the performance of CK-18 M30 to differentiate NASH from NAFL was judged modest, as per data from a meta-analysis of 11 studies [13].”
BackgroundMethodEpidemiology and Natural History of Nonalcoholic Fatty Liver Disease
Satapathy, S., & Sanyal, A. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562943 · Cited by 371 · cited 1×
“The global prevalence is approximately 25%, representing a wide histological spectrum from simple steatosis (NAFL), non-alcoholic steatohepatitis (NASH) [3] to hepatic fibrosis.”
BackgroundMerriman, R. B., Ferrell, L. D., Patti, M. G., Weston, S. R., Pabst, M. S., Aouizerat, B. E., & Bass, N. M. (2006) · Hepatology · doi:10.1002/hep.21346 · Cited by 324
A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)
Younossi, Z. M., Jarrar, M., Nugent, C., Randhawa, M., Afendy, M., Stepanova, M., Rafiq, N., Goodman, Z., Chandhoke, V., & Baranova, A. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9506-y · Cited by 277 · cited 6×
“Younossi 2008 [52] USA 69 (46) NASH 32 Biopsy proven NAFLD NR 27.”
BackgroundMethodInfluentialCusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., Ortiz-Lopez, C., Hecht, J., Feldstein, A. E., Webb, A., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.042 · Cited by 273 · cited 19×
“The thresholds spanned from 111 to 670 U/L.”
BackgroundMethodInfluentialMyers, R. P., Fong, A., & Shaheen, A. A. M. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01691.x · Cited by 269
Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers
Shen, J., Chan, H. L.-Y., Wong, G. L.-H., Choi, P. C.-L., Chan, A. W.-H., Chan, H.-Y., Chim, A. M.-L., Yeung, D. K.-W., Chan, F. K.-L., Woo, J., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.025 · Cited by 246 · cited 1×
“We do acknowledge that other studies including CK-18 in a composite scoring system may exist, despite not being eligible for inclusion in the present systematic review [62, 63].”
ResultBiomarkers of liver cell death
Eguchi, A., Wree, A., & Feldstein, A. E. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.026 · Cited by 220 · cited 2×
“M30 measures the caspase-cleaved CK-18 revealed during apoptosis, while M65 measures the full-length protein, including both caspase-cleaved and intact CK-18, which is released from cells undergoing necrosis [11].”
BackgroundJoka, D., Wahl, K., Moeller, S., Schlue, J., Vaske, B., Bahr, M. J., Manns, M. P., Schulze-Osthoff, K., & Bantel, H. (2012) · Hepatology · doi:10.1002/hep.24734 · Cited by 184 · cited 7×
“Joka 2011 [9] Germany 22 (7) NASH 55 Biopsy proven NAFLD 27 (1) 75.”
BackgroundMethodInfluentialAn apoptosis panel for nonalcoholic steatohepatitis diagnosis
Tamimi, T. I. A.-R., Elgouhari, H. M., Alkhouri, N., Yerian, L. M., Berk, M. P., Lopez, R., Schauer, P. R., Zein, N. N., & Feldstein, A. E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.023 · Cited by 184 · cited 2×
“We further graded four studies with high concern regarding applicability in the patient selection domain [30, 46, 54, 57].”
BackgroundYilmaz, Y. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i6.837 · Cited by 168 · cited 2×
“One study [50] assessed the ability of M65 to detect significant fibrosis; at a threshold of 244 U/L, sensitivity was 0.”
BackgroundDiab, D. L., Yerian, L., Schauer, P., Kashyap, S. R., Lopez, R., Hazen, S. L., & Feldstein, A. E. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.07.016 · Cited by 168 · cited 1×
“Diab 2008 [56] USA 55 (68) NASH 40 Bariatric surgery patients 48 (43– 54) † 23.”
A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis
Younossi, Z. M., Page, S., Rafiq, N., Birerdinc, A., Stepanova, M., Hossain, N., Afendy, A., Younoszai, Z., Goodman, Z., & Baranova, A. (2011) · Obesity Surgery · doi:10.1007/s11695-010-0204-1 · Cited by 162 · cited 2×
“Younossi 2011 [58] USA 79 (61) NASH 51 Biopsy proven NAFLD 47.”
BackgroundAnty, R., Iannelli, A., Patouraux, S., Bonnafous, S., Lavallard, V. J., Senni‐Buratti, M., Ben Amor, I., Staccini‐Myx, A., Saint‐Paul, M. ‐., Berthier, F., et al. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04480.x · Cited by 153
Juluri, R., Vuppalanchi, R., Olson, J., Ünalp, A., Van Natta, M. L., Cummings, O. W., Tonascia, J., & Chalasani, N. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181dd1348 · Cited by 148 · cited 3×
“A five-point scoring system (F0-F4), developed by the NASH clinical research network (NASH CRN) [17], is the most commonly used for fibrosis staging.”
BackgroundInfluentialHe, L., Deng, L., Zhang, Q., Guo, J., Zhou, J., Song, W., & Yuan, F. (2017) · BioMed Research International · doi:10.1155/2017/9729107 · Cited by 126 · cited 2×
“82 [60]; Kwok (2014) (seven studies) reported a summary sensitivity of 0.”
BackgroundInfluentialKazankov, K., Barrera, F., Møller, H. J., Rosso, C., Bugianesi, E., David, E., Ibrahim Kamal Jouness, R., Esmaili, S., Eslam, M., McLeod, D., et al. (2016) · Liver International · doi:10.1111/liv.13150 · Cited by 113 · cited 1×
“Kazankov 2016 [33] Australia, Italy 331 (112) NASH 40 Biopsy proven NAFLD 29.”
BackgroundLiu, X.-L., Pan, Q., Zhang, R.-N., Shen, F., Yan, S.-Y., Sun, C., Xu, Z.-J., Chen, Y.-W., & Fan, J.-G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i44.9844 · Cited by 98 · cited 2×
“Liu 2016 [36] China 48 (13) NASH 65 Biopsy proven NAFLD 26.”
BackgroundAssessment of non‐alcoholic fatty liver disease using serum total cell death and apoptosis markers
Shen, J., Chan, H. L., Wong, G. L., Chan, A. W. H., Choi, P. C., Chan, H., Chim, A. M.-L., Yeung, D. K. ‐., Yu, J. Q., Chu, C. W., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12091 · Cited by 87 · cited 1×
“Shen 2012 [44] China 147 (65) NASH 47 Biopsy proven NAFLD 27.”
BackgroundMalik, R., Chang, M., Bhaskar, K. R., Nasser, I. A., Curry, M. P., Schuppan, D., Byrnes, V., & Afdhal, N. H. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05731.x · Cited by 87 · cited 1×
“Malik 2009 [38] USA 95 (37) NASH 63 Biopsy proven NAFLD 31.”
BackgroundBugianesi, E. (2016) · Diabetologia · doi:10.1007/s00125-016-3930-7 · Cited by 84
Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis
Yang, M., Xu, D., Liu, Y., Guo, X., Li, W., Guo, C., Zhang, H., Gao, Y., Mao, Y., & Zhao, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131664 · Cited by 83 · cited 2×
“Yang 2015 [49] China 179 (93) NASH 38 Biopsy proven NAFLD NR 116 (30.”
BackgroundNon-invasive assessment of NAFLD as systemic disease—A machine learning perspective
Canbay, A., Kälsch, J., Neumann, U., Rau, M., Hohenester, S., Baba, H. A., Rust, C., Geier, A., Heider, D., & Sowa, J.-P. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214436 · Cited by 82 · cited 2×
“81), with even better accuracy for detecting advanced fibrosis [63].”
BackgroundResultBoursier, J., Anty, R., Vonghia, L., Moal, V., Vanwolleghem, T., Canivet, C. M., Michalak, S., Bonnafous, S., Michielsen, P., Oberti, F., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14621 · Cited by 79 · cited 6×
“For significant fibrosis, we included a single threshold value (ranging from 122 to 285 U/L) from five studies [27, 43, 47, 55, 59] with a total of 1,155 participants (554 had significant fibrosis) (S6 Fig in S1 File).”
BackgroundMethodInfluentialSelf-citationKamada, Y., Akita, M., Takeda, Y., Yamada, S., Fujii, H., Sawai, Y., Doi, Y., Asazawa, H., Nakayama, K., Mizutani, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066328 · Cited by 78 · cited 3×
“A sensitivity analysis was conducted excluding four studies with two or more domains of high risk of bias or applicability concerns [9, 10, 31, 40] for M30 and NASH.”
BackgroundMethodCao, W. J., Zhao, C., Shen, C., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082092 · Cited by 77 · cited 1×
“Cao 2013 [22] China 95 (73) NASH 46 Biopsy proven or clinical suspicion of NAFLD 28.”
BackgroundTesting for publication bias in diagnostic meta‐analysis: a simulation study
Bürkner, P., & Doebler, P. (2014) · Statistics in Medicine · doi:10.1002/sim.6177 · Cited by 73
Kawanaka, M., Nishino, K., Nakamura, J., Urata, N., Oka, T., Goto, D., Suehiro, M., Kawamoto, H., & Yamada, G. (2015) · Annals of Hepatology · doi:10.5604/16652681.1171767 · Cited by 58 · cited 2×
“Kawanka 2015 [32] Japan 146 (78) NASH 71 Biopsy proven NAFLD 26.”
BackgroundGrigorescu, M., Crişan, D., Radu, C., Grigorescu, M., Sparchez, Z. A., & Serban, A. (2012) · PubMed · Cited by 55
Serum cytokeratin‐18 in the diagnosis of non‐alcoholic steatohepatitis: A meta‐analysis
Chen, J., Zhu, Y., Zheng, Q., & Jiang, J. (2014) · Hepatology Research · doi:10.1111/hepr.12197 · Cited by 48
Chuah, K., Wan Yusoff, W. N. I., Sthaneshwar, P., Nik Mustapha, N. R., Mahadeva, S., & Chan, W. (2019) · Liver International · doi:10.1111/liv.14084 · Cited by 48 · cited 4×
“MACK-3 showed more promise for detecting fibrotic NASH, but the evidence is still limited to two studies, and the model presents with limitations such as adequate performance among subgroups with metabolic syndrome and a large gap of patients who lie between the high and low threshold values [24, 55].”
BackgroundMethodInfluentialDvorak, K., Stritesky, J., Petrtyl, J., Vitek, L., Sroubkova, R., Lenicek, M., Smid, V., Haluzik, M., & Bruha, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111551 · Cited by 47 · cited 2×
“Dvorak 2014 [26] Czech Republic 56 (NR) NASH 68 Biopsy proven NAFLD 29.”
BackgroundSerum Apoptotic Caspase Activity in Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease
Papatheodoridis, G. V., Hadziyannis, E., Tsochatzis, E., Georgiou, A., Kafiri, G., Tiniakos, D. G., Margariti, K., Manolakopoulos, S., Manesis, E. K., & Archimandritis, A. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c0945a · Cited by 43 · cited 1×
“Papatheodoridis 2010 [41] Greece 58 (26) NASH 52 Biopsy proven NAFLD 28.”
BackgroundDarweesh, S. K., Abdelaziz, R., Abdelfatah, D., AbdElazim, N. A., Fathi, S. A., Attia, D. I., & AbdAllah, M. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001385 · Cited by 41 · cited 1×
“Only three studies were classified as at high risk of bias for flow and timing [10, 25, 40].”
BackgroundZheng, K. I., Liu, W., Pan, X.-Y., Ma, H., Zhu, P., Wu, X., Targher, G., Byrne, C. D., Wang, X., Chen, Y., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001174 · Cited by 41 · cited 5×
“Among the 18 studies that used the M30 Apoptosense ELISA by PEVIVA, the AUC was 0.74 (95% CI: 0.67; 0.80), with paired sensitivity and specificity of 0.60 (95% CI: 0.49; 0.70) and 0.80 (95% CI: 0.70; 0.87), respectively.”
MethodInfluentialAida, Y., Abe, H., Tomita, Y., Nagano, T., Seki, N., Sugita, T., Itagaki, M., Ishiguro, H., Sutoh, S., & Aizawa, Y. (2014) · Europe PMC (PubMed Central) · Cited by 40
Chan, W., Sthaneshwar, P., Mustapha, N. R. N., & Mahadeva, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105903 · Cited by 40 · cited 1×
“Chan 2014 [23] Malaysia 93 (48) NASH 42 US diagnosed NAFLD 29.”
BackgroundKim, Y. S., Jung, E. S., Hur, W., Bae, S. H., Choi, J. Y., Song, M. J., Kim, C. W., Jo, S. H., Lee, C. D., Lee, Y. S., et al. (2013) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2013.19.2.120 · Cited by 38 · cited 1×
“Kim 2013 [34] Korea 108 (35) NASH 62 Biopsy proven NAFLD 28.”
BackgroundMusso, G., Gambino, R., Durazzo, M., & Cassader, M. (2009) · Hepatology · doi:10.1002/hep.23255 · Cited by 38 · cited 10×
“A sensitivity analysis was conducted excluding four studies with two or more domains of high risk of bias or applicability concerns [9, 10, 31, 40] for M30 and NASH.”
BackgroundMethodInfluentialLiu, W., Zheng, K. I., Pan, X., Ma, H., Zhu, P., Wu, X., Rios, R. S., Targher, G., Byrne, C. D., Wang, X., et al. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14894 · Cited by 36 · cited 1×
“Ten studies were scored as high risk of bias in the patient selection domain [9, 10, 29, 31, 36, 37, 40, 47, 50, 58].”
BackgroundYounes, R., Rosso, C., Petta, S., Cucco, M., Marietti, M., Caviglia, G. P., Ciancio, A., Abate, M. L., Cammà, C., Smedile, A., et al. (2017) · Liver International · doi:10.1111/liv.13612 · Cited by 35 · cited 2×
“For advanced fibrosis, five studies [27, 42, 43, 51, 55] were included in the meta-analysis (1,513 participants, 313 with advanced fibrosis) (S8 Fig in S1 File).”
BackgroundRosso, C., Caviglia, G. P., Abate, M. L., Vanni, E., Mezzabotta, L., Touscoz, G. A., Olivero, A., Marengo, A., Rizzetto, M., Bugianesi, E., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.09.008 · Cited by 33 · cited 3×
“Two studies [27, 43] investigated the combined use of M30 with transient elastography (TE) (FibroScan) to detect fibrosis.”
BackgroundPîrvulescu, I., Gheorghe, L., Csiki, I. E., Becheanu, G., Dumbravă, M., Fica, S. V., Martin, S., Sarbu, A. E., Gheorghe, C., Diculescu, M. M., et al. (2012) · PubMed · Cited by 31
Kobayashi, N., Kumada, T., Toyoda, H., Tada, T., Ito, T., Kage, M., Okanoue, T., & Kudo, M. (2017) · Digestive Diseases · doi:10.1159/000480142 · Cited by 31
Liebig, S., Stöckmann, N., Geier, A., Rau, M., Schattenberg, J. M., Bahr, M. J., Manns, M. P., Jaeckel, E., Schulze‐Osthoff, K., & Bantel, H. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000066 · Cited by 30 · cited 1×
“CK-18 can potentially improve risk stratification in combination with other synergistic markers, such as TE or NFS, by testing for elevated M30 levels among patients under the low threshold or in patients with intermediate TE/NFS values (between the high and low threshold) [64].”
BackgroundTada, T., Kumada, T., Toyoda, H., Saibara, T., Ono, M., & Kage, M. (2018) · Biomarkers · doi:10.1080/1354750x.2018.1425915 · Cited by 27 · cited 1×
“Tada 2018 [45] Japan 170 (91) NASH 76 Biopsy proven NAFLD 27.”
BackgroundPoor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH
Pimentel, C. F. M. G., Jiang, Z. G., Otsubo, T., Feldbrügge, L., Challies, T. L., Nasser, I. A., Robson, S. C., Afdhal, N. H., & Lai, M. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3916-1 · Cited by 25 · cited 7×
“For advanced fibrosis, five studies [27, 42, 43, 51, 55] were included in the meta-analysis (1,513 participants, 313 with advanced fibrosis) (S8 Fig in S1 File).”
BackgroundMethodResultInfluentialHuang, J., Yeh, M., Huang, C., Huang, C., Tsai, P., Tai, C., Yang, H., Dai, C., Hsieh, M., Chen, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174394 · Cited by 19 · cited 2×
“We further graded four studies with high concern regarding applicability in the patient selection domain [30, 46, 54, 57].”
BackgroundYilmaz, Y. N., Ulukaya, E., & Dolar, E. (2008) · Hepatology · doi:10.1002/hep.22691 · Cited by 17
Ergelen, R., Akyüz, Ü., Aydın, Y., Eren, F., & Yilmaz, Y. N. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000342 · Cited by 15 · cited 4×
“93) did not significantly improve the diagnostic ability from either TE or CK-18 as a stand-alone test [27].”
BackgroundInfluentialValva, P., Rios, D. A., Casciato, P. C., Gadano, A. C., Galdame, O., Müllen, E., Bertot, G. M., Matteo, E. D., & Preciado, M. V. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001079 · Cited by 12 · cited 2×
“For significant fibrosis, we included a single threshold value (ranging from 122 to 285 U/L) from five studies [27, 43, 47, 55, 59] with a total of 1,155 participants (554 had significant fibrosis) (S6 Fig in S1 File).”
BackgroundMohammed, M. A., Omar, N. M., Mohammed, S. A., Amin, A. M., & Gad, D. F. (2019) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2019.457.466 · Cited by 11 · cited 1×
“Mohammed 2019 [39] Egypt 62 (62) NASH 66 US proven NAFLD 30.”
BackgroundUsefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population
Hasegawa, Y., Kim, S. R., Hatae, T., Ohta, M., Fujinami, A., Sugimoto, K., Kim, K. I., Imoto, S., Tohyama, M., Kim, S. K., et al. (2015) · Digestive Diseases · doi:10.1159/000439076 · Cited by 9 · cited 3×
“Hasegawa 2015 [29] Japan 41 (7) NASH 49 US and CT diagnosed NAFLD NR 75.”
BackgroundZheng, K. I., Liu, W., Pan, X., Ma, H.-L., Zhu, P., Wu, X., Targher, G., Byrne, C. D., Wang, X., Chen, Y., et al. (2020) · Journal of Hepatology · doi:10.1016/s0168-8278(20)31322-2 · Cited by 3
Cited by
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
“A recent meta-analysis proposed K-18 values between 127–191 U l −1 for ruling-out MASH at fixed sensitivity levels and 304–399 U l −1 to rule-in MASH at fixed specificity levels 32 .”
BackgroundDuseja, A. K., Singh, S. P., De, A., Madan, K., Rao, P. N., Shukla, A., Choudhuri, G., Saigal, S., Shalimar, S., Arora, A., et al. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.014 · Cited by 119
Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
Qadri, S. U., Ahlholm, N., Lønsmann, I., Pellegrini, P., Poikola, A., Luukkonen, P. K., Porthan, K., Juuti, A., Sammalkorpi, H. E., Penttilä, A. K., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab933 · Cited by 67
Epigenetics of Hepatic Insulin Resistance
Maude, H., Sanchez-Cabanillas, C., & Cebola, I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.681356 · Cited by 69
Metadata
- Authors
- Lee, J., Vali, Y., Boursier, J., Duffin, K., Verheij, J., Brosnan, M. J., Zwinderman, K., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H.
- Affiliations
- Amsterdam University Medical Centers (NL)
- Centre Hospitalier Universitaire d'Angers (FR)
- Eli Lilly (United States) (US)
- Pfizer (United States) (US)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Corresponding author
- Lee, Jenny
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-09-11
- Volume
- 15
- Issue
- 9
- Pages
- e0238717
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7485872
- OpenAlex
- W3084487116
- Cited by
- 74
- References
- 66
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 15 · 2023: 20 · 2022: 12 · 2021: 11
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Innovative Medicines Initiative (777377)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- cytokeratin 18, M30, M65, nonalcoholic steatohepatitis, liver fibrosis, non-alcoholic fatty liver disease, circulating biomarkers, diagnostic accuracy, hepatocyte death, liver biopsy
- MeSH terms
- Adult, Biopsy, Female, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Peptide Fragments, Biomarkers, Cell Death, Hepatocytes, Keratin-18, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.